Advances in Cancer Immunotherapy™ 2017 Video Series

Class Description

aci17-sitc-clr.jpg
Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are used as content for online courses. One video has been selected for each topic of the 2017 ACI program (twelve total modules).

The online modules will facilitate understanding of the clinical applications of immunotherapy for disease states with FDA-approved treatments; strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting; and the identification and management of immune-related adverse events.

You may complete any of the modules in the order you choose. Each module can be completed independently for continuing education credit. To access any of the modules listed below, select the "Register/Access Class" button to the right. After completing a brief registration form, you will be able select the module(s) you wish to complete.  


Educational Objectives 
  • Describe the rationale for common approaches to cancer immunotherapy.
  • Identify the appropriate clinical management of common side effects of immunotherapy agents.
  • Implement cancer immunotherapy treatments for melanoma, lung, genitourinary, head and neck, and/or hematologic cancers into clinical practice appropriately.
  • Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.
  • Provide appropriate care and counsel for patients receiving immunotherapy and their families.
  • Provide accurate and appropriate counsel on immunotherapy as part of the treatment team.

Target Audience
These modules have been designed to meet the educational needs of physicians, pharmacists, registered nurses and other healthcare professionals involved in the care of patients with cancer.

Media

Internet Activity 

Module 1: Basic Principles of Cancer Immunotherapy

Monica Thakar, MD – Medical College of Wisconsin

  • Physicians – maximum of 0.5 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.5 contact hours (0.5 CEUs)
  • Nurses – 0.6 contact hours, with 0.1 pharmacotherapy contact hours

Module 2: Immunotherapy for the Treatment of Melanoma

Marlana Orloff, MD – Thomas Jefferson University Hospital

  • Physicians – maximum of 0.5 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.5 contact hours (0.5 CEUs)
  • Nurses – 0.5, with 0.2 pharmacotherapy contact hours

Module 3: Immunotherapy for the Treatment of Lung Cancer

Ticiana A. Leal, MD – University of Wisconsin Carbone Cancer Center

  • Physicians – maximum of 0.75 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.75 contact hours (0.75 CEUs)
  • Nurses – 0.6 contact hours, with 0.3 pharmacotherapy contact hours

Module 4: Immunotherapy for the Treatment of Genitourinary Cancers

Douglas G. McNeel, MD, PhD – University of Wisconsin Carbone Cancer 

  • Physicians – maximum of 0.5 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.5 contact hours (0.025 CEUs)
  • Nurses – 0.5 contact hours, with 0.3 pharmacotherapy contact hours

Module 5: Immunotherapy for the Treatment of Hematologic Malignancies

Timothy S. Fenske, MD – Medical College of Wisconsin 

  • Physicians – maximum of 0.5 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.5 contact hours (0.025 CEUs)
  • Nurses – 0.6 contact hours, with 0.3 pharmacotherapy contact hours

Module 6: Immunotherapy for the Treatment of Head and Neck Cancers

Joshua Bauml, MD – University of Pennsylvania

  • Physicians – maximum of 0.5 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.5 contact hours (0.05 CEUs)
  • Nurses – 0.5 contact hours, with 0.2 pharmacotherapy contact hours

Module 7: Effective Practices for Incorporating Immunotherapy into Hospital Operations 

Sigrun Hallmeyer, MD – Advocate Medical Group

  • Physicians – maximum of 0.75 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.75 contact hours (0.75 CEUs)
  • Nurses – 0.8 contact hours

Module 8: Coverage and Reimbursement Challenges and Strategies

Sigrun Hallmeyer, MD – Advocate Medical Group

  • Physicians – maximum of 0.75 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.75 contact hours (0.75 CEUs)
  • Nurses – 0.7 contact hours

Module 9: Mechanisms of Immune-Related Adverse Events

Justine V. Cohen, DO – Massachusetts General Hospital

  • Physicians – maximum of 0.5 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.5 contact hours (0.5 CEUs)
  • Nurses – 0.4 contact hours

Module 10: Nursing Perspective on irAEs: Patient Education, Monitoring and Management 

Ellen Napier, CRNP – University of Pennsylvania

  • Physicians – maximum of 0.5 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.5 contact hours (0.5 CEUs)
  • Nurses – 0.4 contact hours, with 0.3 pharmacotherapy contact hours

Module 11: Management and Mitigation of irAEs for Immunotherapy Prescribers 

Kathleen Madden, MSN, FNP-BC, AOCNP, APHN – New York University Cancer Institute

  • Physicians – maximum of 0.5 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.5 contact hours (0.5 CEUs)
  • Nurses – 0.4 contact hours, with 0.1 pharmacotherapy contact hours

Module 12: Identification and Management of Immune-Related Adverse Events in the Emergency Setting

Ronny Mario Otero MD, FAAEM - University of Michigan

  • Physicians – maximum of 0.5 AMA PRA Category 1 Credit(s)™
  • Pharmacists – 0.5 contact hours (0.5 CEUs)
  • Nurses – 0.5 contact hours, with 0.2 pharmacotherapy contact hours

More Information

Target Audience
Clinician Icon

Credit Available
Oct. 6, 2017- Sept. 30, 2018

Approximate Time to Complete
0.5 hours per module
6.75 hours total

Credits

  • CME:maximum of 6.75 AMA PRA Category 1 Credits™
  • CNE: maximum of 6.5 contact hours, with 2.0 pharmacotherapy contact hours
  • CPE: maximum of 6.75 contact hours
Cost
Free

Register/Access Class 

Please use one of the following Internet browsers to open this activity: Chrome, Firefox, or Safari browsers in order to view this online activity.

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer 

The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from 
Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc. and Prometheus Laboratories Inc.